Immunotherapy engagement in pancreatic adenocarcinoma: Provisional results of iLSTA study- Durvalumab, LSTA1 (certepetide), gemcitabine, and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma.

被引：0
|
作者：
Dean, Andrew Peter
Johansson, Mikael
Yusoff, Ian
Rao, Samarth
Sparrow, Susan
Kumarasinghe, Priyanthi
Navadgi, Suresh
Watanabe, Yuki
Webber, Laurence
Grew, Jenny
Fitzgerald, Shane
Comito, Olivia Rose
机构：
[1] St John God Subiaco Hosp, Subiaco, Australia
[2] Dept Upper GI Surg, Nedlands, Australia
[3] Sir Charles Gairdner Hosp, Nedlands, Australia
[4] Australian Clin Labs, Subiaco, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Lu, Ming
    Shen, Lin
    Zhou, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12657 - 12666
  • [32] Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC)
    Chiritescu, G.
    Dumon, K.
    Verslype, C.
    Prenen, H.
    Houbiers, G.
    Peeters, M.
    Janssens, J.
    Van Daele, D.
    Laurent, S.
    Arts, J.
    Hendrickx, K.
    Borbath, I.
    Ferrante, M.
    Bastin, F.
    Goeminne, J.
    Van Laethem, J.
    Vanderstraeten, E.
    Decaestecker, J.
    Van Vaerenbergh, W.
    Delhougne, B.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 101 - 101
  • [33] Final results for gemcitabine with nab-paclitaxel in neoadjuvant treatment of resectable pancreatic adenocarcinoma: GAIN-1 study
    Sliesoraitis, Sarunas
    Desai, Neelam Vijay
    Trevino, Jose Gilberto
    Hughes, Steven J.
    Ziotecki, Robert
    Lightsey, Judith L.
    Ivey, Alison Marguerite
    Allegra, Carmen Joseph
    Dang, Long H.
    Daily, Karen Colleen
    Behrns, Kevin
    Liu, Chen
    Chauhan, Shailendra
    Collinsworth, Amy L.
    Lu, Xiaomin
    George, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma
    Naru Kondo
    Yoshiaki Murakami
    Kenichiro Uemura
    Takeshi Sudo
    Yasushi Hashimoto
    Naoya Nakagawa
    Shinya Takahashi
    Hiroki Ohge
    Taijiro Sueda
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 775 - 781
  • [35] A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma
    Kondo, Naru
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Sudo, Takeshi
    Hashimoto, Yasushi
    Nakagawa, Naoya
    Takahashi, Shinya
    Ohge, Hiroki
    Sueda, Taijiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 775 - 781
  • [36] PANOVA-3: A phase 3 study of tumor treating fields with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma.
    Picozzi, Vincent J.
    Finlay, Judith
    Macarulla, Teresa
    Philip, Philip A.
    Becerra, Carlos R.
    Dragovich, Tomislav
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Blaydorn, Lisa
    Beck, Julia
    Bornemann-Kolatzki, Kirsten
    Urnovitz, Howard
    Schutz, Ekkhard
    Khemka, Vivek
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 96 - 102
  • [38] NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
    Ferdinando De Vita
    Jole Ventriglia
    Antonio Febbraro
    Maria Maddalena Laterza
    Alessio Fabozzi
    Beatrice Savastano
    Angelica Petrillo
    Anna Diana
    Guido Giordano
    Teresa Troiani
    Giovanni Conzo
    Gennaro Galizia
    Fortunato Ciardiello
    Michele Orditura
    BMC Cancer, 16
  • [39] Development of extensive hepatic steatosis during treatment with nab-paclitaxel and gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma
    Vogl, U. M.
    Vormittag, L.
    Kafka, A.
    Heinrich, B.
    Roessler, L.
    Stuebler, J.
    Schima, W.
    Oehler, L.
    ONKOLOGIE, 2013, 36 : 74 - 74
  • [40] Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
    Peterson, Shawn L.
    Husnain, Muhammad
    Pollack, Terri
    Pimentel, Agustin
    Loaiza-Bonilla, Arturo
    Westendorf-Overley, Colleen
    Ratermann, Kelley
    Anthony, Lowell
    Desimone, Philip
    Goel, Gaurav
    Kudrimoti, Mahesh
    Dineen, Sean
    Tzeng, Ching-Wei D.
    Hosein, Peter J.
    ANTICANCER RESEARCH, 2018, 38 (07) : 4035 - 4039
12345